The FDA gave two new clearances to Propeller Health for sensors that can now be marketed to improve medication adherence when used with two different inhalers, according to MobiHealthNews.
“What we’ve done is put a lot of work into engineering a solution that doesn’t require the person to do anything, but then uses a lot of electronic means to understand when those medications are delivered,” Propeller CEO David Van Sickle told MobiHealthNews. “A lot of different sensors are used to measure the actuation when there isn’t a simple linear path of force that we can monitor like we could with the MDI.”
This is an exciting advancement since the previous clearances on similar monitors were for just tracking and not adherence.
Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from GlaxoSmithKline and the Respimat inhaler from Boehringer Ingelheim. Unlike previous FDA clearances for Propeller, the new clearances actually allow Propeller to market its new devices as [ ].